Bavarian Nordic reacts to call for fair price for mpox vaccine

In an interview with Danish national public radio broadcast station DR, Henrik Juuel, chief financial officer of vaccine maker Bavarian Nordic (OMX: BAVA), reacted to public calls for the company to lower the price of its mpox vaccine.

Bavarian Nordic is the only drugmaker with a US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved mpox vaccine, with its Jynneos, also marketed under the trade name Imvanex in Europe. Late last month, Emergent BioSolutions (NYSE: EBS) gained US regulatory approval for its mpox vaccine, ACAM2000.

In late August, Public Citizen sent a letter to CEO Paul Chaplin urging Bavarian Nordic to prioritize public health amid the global mpox emergency and lower the price of Jynneos. The World Health Organization (WHO) estimates mpox vaccines will cost $50 to $75 each, but the definite price of Jynneos remains unknown. The letter outlines how concealing and refusing to lower the price of Jynneos appears to be a move to exploit the latest global health crisis.